Global Information
회사소개 | 문의

세계의 아토피 피부염 치료제 시장 예측

Global Atopic Dermatitis Drugs Market Forecast 2019-2027

리서치사 Inkwood Research
발행일 2018년 10월 상품 코드 626309
페이지 정보 영문 130 Pages
가격
US $ 2,500 ₩ 2,856,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,427,200 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,140,800 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 아토피 피부염 치료제 시장 예측 Global Atopic Dermatitis Drugs Market Forecast 2019-2027
발행일 : 2018년 10월 페이지 정보 : 영문 130 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

세계의 아토피 피부염 치료제(Atopic Dermatitis Drugs) 시장 전망에 대해 분석했으며, 제품 개요와 시장 구조, 주요 시장 성장 촉진·억제요인, 전체적인 시장 규모 동향 전망(향후 9년간), 작용기서별·약제 클래스별·지역별 동향, 관련 산업과의 연관 구조와 시장 기회, 시장 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.

제1장 분석 범위

제2장 분석 방법

제3장 주요 요약

제4장 시장 역학

  • 서론 : 아토피 피부염
  • 시장 정의와 범위
  • 법률상·정책상·규제상 과제
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 과제

제5장 작용기서(ROA)별 시장

  • 국소약
  • 경구약
  • 주사약

제6장 약제 클래스별 시장

  • 국소적 항생물질
  • 국소적 항히스타민제
  • 국소적 코르티코스테로이드
  • 국소적 보습제/연화제
  • 국소적 칼시뉴린 억제제
  • 면역조절제
  • 비공식(오프라벨) 요법
  • 전신성 의약품
  • PDE-4 억제제
  • 인터루킨 억제제

제7장 주요 분석 지표

  • Porter's Five Forces 분석
  • 시장 기회 매트릭스
  • 벤더 상황
  • 파이프라인 분석

제8장 지역별 분석

  • 북미(미국, 캐나다)
  • 유럽(독일, 프랑스, 영국, 러시아 등)
  • 아시아태평양(인도, 중국, 일본, 호주 및 뉴질랜드, 한국 등)
  • 기타 국가(RoW : 라틴아메리카, 중동 및 아프리카)

제9장 기업 개요

  • ALLERGAN PLC.
  • AQUA PHARMACEUTICALS(ALMIRALL COMPANY의 자회사)
  • ASTELLAS PHARMA INC.
  • BAYER AG
  • BIOFRONTERA AG
  • BRISTOL-MYERS SQUIBB
  • STIEFEL LABORATORIES INC
  • ENCORE DERMATOLOGY
  • GALDERMA SA
  • LEO PHARMA
  • MEDA PHARMACEUTICALS(MYLAN)
  • NOVARTIS AG
  • PFIZER
  • REGENERON PHARMACEUTICALS
  • SANOFI SA
  • VALENT PHARMACEUTICAL INC.
KSM 18.05.02

영문목차

KEY FINDINGS

According to market expectations, the global atopic dermatitis drugs market should grow with a CAGR of 4.77% over the forecast period. The base year considered for the study is 2017 and the forecast period is 2019-2027.

The global atopic dermatitis drugs market is primarily driven by factors such as the increasing prevalence of food allergies causing atopic dermatitis, the rising focus on systematic therapies and the ever increasing use of pharmacological products in developing countries

MARKET INSIGHTS

The important driver increasing growth in the global atopic dermatitis drugs market is the high prevalence of food allergies exacerbating atopic dermatitis. It is estimated that food allergy and severe atopic dermatitis coexist in about one-third of all children with atopic dermatitis. The atopic dermatitis drugs market is broadly classified into two segments on the basis of drug classes and the route of administration.

REGIONAL INSIGHTS

This report broadly segregates the atopic dermatitis drug market into four geographies namely-Europe, Asia-Pacific, North America and Rest of the World. The atopic dermatitis drugs market in North America is expected to hold the largest share by 2027. This sudden yet steady growth in the North American regional market is attributed to the high prevalence of allergic conditions in the existing population. The United States holds the largest revenue share in global atopic dermatitis drugs market country-wise.

COMPETITIVE INSIGHTS

Leading players in the global atopic dermatitis drug market are Allergan Plc, Aqua Pharmaceuticals (An Almirall Company), Astellas Pharma Inc., Bayer Ag, Biofrontera Ag,Bristol-Myers Squibb,Stiefel Laboratories Inc, Encore Dermatology, Galderma Sa, Leo Pharma, Meda Pharmaceuticals (Mylan N.V.),Novartis Ag, Pfizer, Regeneron Pharmaceuticals, Sanofi Sa, Valent Pharmaceutical Inc. and several others.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. NORTH AMERICA GENERATED LARGEST CHUNK OF THE GLOBAL REVENUE
    • 3.2.2. TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY OF THE OVERALL MARKET SHARE
    • 3.2.3. INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
    • 4.1.2. GROWING FOCUS ON SYSTEMATIC THERAPIES
    • 4.1.3. INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. STRINGENT REGULATIONS FOR PRODUCT APPROVAL
    • 4.2.2. GENERIC COMPETITION
  • 4.3. MARKET OPPORTUNITIES
    • 4.3.1. INCREASING M&A LEADING TO MARKET CONSOLIDATION
    • 4.3.2. LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
    • 4.3.3. GROWING FOCUS ON NOVEL DRUGS
  • 4.4. MARKET CHALLENGES
    • 4.4.1. BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
    • 4.4.2. HIGHLY GENERICIZED MARKET
    • 4.4.3. POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE

5. MARKET SEGMENTATION

  • 5.1. MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
    • 5.1.1. TOPICAL
    • 5.1.2. ORAL
    • 5.1.3. INJECTIBLES
  • 5.2. MARKET BY DRUG CLASS 2019-2027
    • 5.2.1. TOPICAL ANTIBIOTICS
    • 5.2.2. TOPICAL ANTIHISTAMINES
    • 5.2.3. TOPICAL CORTICOSTEROIDS
    • 5.2.4. TOPICAL MOISTURIZERS/EMOLLIENTS
    • 5.2.5. TOPICAL CALCINEURIN INHIBITORS
    • 5.2.6. IMMUNOMODULATORS
    • 5.2.7. OFF-LABEL THERAPIES
    • 5.2.8. SYSTEMIC AGENTS
    • 5.2.9. PDE4 INHIBITOR
    • 5.2.10. INTERLEUKIN INHIBITOR

6. KEY ANALYTICS

  • 6.1. PORTERS FIVE FORCES ANALYSIS
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE
    • 6.1.3. BARGAINING POWER OF SUPPLIERS
    • 6.1.4. BARGAINING POWER OF BUYERS
    • 6.1.5. THREAT OF COMPETITIVE RIVALRY
  • 6.2. OPPORTUNITY MATRIX
  • 6.3. PIPELINE ANALYSIS
  • 6.4. LEGAL, POLICY AND REGULATORY ISSUES

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. GERMANY
    • 7.2.2. FRANCE
    • 7.2.3. THE UNITED KINGDOM
    • 7.2.4. RUSSIA
    • 7.2.5. ITALY
    • 7.2.6. REST OF EUROPE
  • 7.3. ASIA-PACIFIC
    • 7.3.1. INDIA
    • 7.3.2. CHINA
    • 7.3.3. JAPAN
    • 7.3.4. AUSTRALIA AND NEW ZEALAND
    • 7.3.5. SOUTH KOREA
    • 7.3.6. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST AND AFRICA

8. COMPANY PROFILES

  • 8.1. ALLERGAN PLC
    • 8.1.1. COMPANY OVERVIEW
    • 8.1.2. PRODUCT PORTFOLIO
    • 8.1.3. SWOT ANALYSIS
    • 8.1.4. STRATEGIC INITIATIVES
  • 8.2. AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
    • 8.2.1. COMPANY OVERVIEW
    • 8.2.2. PRODUCT PORTFOLIO
    • 8.2.3. SWOT ANALYSIS
  • 8.3. ASTELLAS PHARMA INC.
    • 8.3.1. COMPANY OVERVIEW
    • 8.3.2. PRODUCT PORTFOLIO
    • 8.3.3. SWOT ANALYSIS
    • 8.3.4. STRATEGIC INITIATIVES
  • 8.4. BAYER AG
    • 8.4.1. COMPANY OVERVIEW
    • 8.4.2. PRODUCT PORTFOLIO
    • 8.4.3. SWOT ANALYSIS
    • 8.4.4. STRATEGIC INITIATIVES
  • 8.5. BIOFRONTERA AG
    • 8.5.1. COMPANY OVERVIEW
    • 8.5.2. PRODUCT PORTFOLIO
    • 8.5.3. SWOT ANALYSIS
  • 8.6. BRISTOL-MYERS SQUIBB
    • 8.6.1. COMPANY OVERVIEW
    • 8.6.2. PRODUCT PORTFOLIO
    • 8.6.3. SWOT ANALYSIS
  • 8.7. STIEFEL LABORATORIES, INC
    • 8.7.1. COMPANY OVERVIEW
    • 8.7.2. PRODUCT PORTFOLIO
    • 8.7.3. SWOT ANALYSIS
  • 8.8. ENCORE DERMATOLOGY
    • 8.8.1. COMPANY OVERVIEW
    • 8.8.2. PRODUCT PORTFOLIO
    • 8.8.3. SWOT ANALYSIS
    • 8.8.4. STRATEGIC INITIATIVES
  • 8.9. GALDERMA SA
    • 8.9.1. COMPANY OVERVIEW
    • 8.9.2. PRODUCT PORTFOLIO
    • 8.9.3. SWOT ANALYSIS
    • 8.9.4. STRATEGIC INITIATIVES
  • 8.10. LEO PHARMA
    • 8.10.1. COMPANY OVERVIEW
    • 8.10.2. PRODUCT PORTFOLIO
    • 8.10.3. SWOT ANALYSIS
    • 8.10.4. STRATEGIC INITIATIVES
  • 8.11. MEDA PHARMACEUTICALS (MYLAN N.V.)
    • 8.11.1. COMPANY OVERVIEW
    • 8.11.2. PRODUCT PORTFOLIO
    • 8.11.3. SWOT ANALYSIS
    • 8.11.4. STRATEGIC INITIATIVES
  • 8.12. NOVARTIS AG
    • 8.12.1. COMPANY OVERVIEW
    • 8.12.2. PRODUCT PORTFOLIO
    • 8.12.3. SWOT ANALYSIS
    • 8.12.4. STRATEGIC INITIATIVES
  • 8.13. PFIZER
    • 8.13.1. COMPANY OVERVIEW
    • 8.13.2. PRODUCT PORTFOLIO
    • 8.13.3. SWOT ANALYSIS
    • 8.13.4. STRATEGIC INITIATIVES
  • 8.14. REGENERON PHARMACEUTICALS
    • 8.14.1. COMPANY OVERVIEW
    • 8.14.2. PRODUCT PORTFOLIO
    • 8.14.3. SWOT ANALYSIS
    • 8.14.4. STRATEGIC INITIATIVES
  • 8.15. SANOFI SA
    • 8.15.1. COMPANY OVERVIEW
    • 8.15.2. PRODUCT PORTFOLIO
    • 8.15.3. SWOT ANALYSIS
    • 8.15.4. STRATEGIC INITIATIVES
  • 8.16. VALENT PHARMACEUTICAL INC.
    • 8.16.1. COMPANY OVERVIEW
    • 8.16.2. PRODUCT PORTFOLIO
    • 8.16.3. SWOT ANALYSIS

TABLE LIST

  • TABLE 1 GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 2 RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
  • TABLE 3 GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)
  • TABLE 4 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN ORAL ROA BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 18 PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
  • TABLE 19 REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET
  • TABLE 20 GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
  • TABLE 21 NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 22 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 23 ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 24 REST OF THE WORLD ATOPIC DERMATITIS DRUGS MARKET 2019-2027 (IN $ MILLION)

FIGURES LIST

  • FIGURE 1 GLOBAL ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 THE UNITED STATES ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 3 CANADA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 4 GERMANY ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 5 FRANCE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 6 THE UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 7 RUSSIA ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 8 ITALY ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 9 REST OF EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 10 INDIA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 11 CHINA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 12 JAPAN ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 13 AUSTRALIA AND NEW ZEALAND ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 14 SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 15 REST OF ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 16 LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 (IN $ MILLION)
  • FIGURE 17 MIDDLE EAST AND AFRICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 (IN $ MILLION)
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research